$EBS News

Emergent BioSolutions stock falls as CFO plans retirement

Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl

Emergent Biosolutions Appoints Treasurer Frank Vargo As Interim CFO, Effective Jan. 1, 2027, Succeeding Richard Lindahl

Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026

Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility

Emergent: The MCM Engine Runs, But Naloxone Is Breaking Down

HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $10 Price Target

Emergent BioSolutions - Tough 2026 Outlook Warrant Rating Downgrade

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Emergent BioSolutions Receives ~$24M Contract Modification From Biomedical Advanced Research And Development Authority For Strategic Preparedness Response Within U.S. Department Of Health And Human Services To Provide CYFENDUS

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

Emergent BioSolutions Receives Canada's Offer To Provide NARCAN Nasal Spray, Effective Oct. 1 Through September 2029

JP Morgan Reinstates Underweight on Emergent BioSolutions

Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript

HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $10

Emergent Biosolutions Q2 Earnings Call Highlights

Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript

Emergent BioSolutions Inc. Q2 2026 Earnings Call Summary